Abstract
Several investigations have been performed to examine the influence of the β-fibrinogen (FGβ) gene polymorphisms on the risk of ischemic stroke, but the results of these studies are controversial. Our study aimed at investigating whether the FGβ gene (-148 C/T, 448 G/A, and -854 G/A) polymorphisms were associated with susceptibility to ischemic stroke by conducting meta-analysis. Relevant studies were identified from 4 Chinese databases, PUBMED and EMBASE before May 30, 2014. The strength of association was evaluated by the odds ratio with 95% confidence interval. Inconsistency index and the Cochran's Q statistic were used to check heterogeneity. Publication bias was tested using funnel plots and Egger's regression test. Thirty-two independent studies with 4311 cases and 4124 controls were included. Significant association between -148 C/T polymorphism and the risk of ischemic stroke was found in overall analysis and middle-age, but not in young adults and elderly people. Similarly, association was also observed for -854 G/A polymorphism, especially in cerebral arterial main trunk infarction (MCI) and cerebral penetrating arterial infarction (PCI). However, no significance was found between 448 G/A polymorphism and ischemic stroke in Chinese people; likewise, no evidence of a significant association was observed when stratified according to the subtype of ischemic stroke (MCI and PCI). These results suggest that -148 C/T and -854 G/A polymorphisms probably contribute to susceptibility of ischemic stroke.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.